Abstract: Certain hexahydro-pyrrolo-isoquinoline compounds are histamine H3 receptor and serotonin transporter modulators useful in the treatment of histamine H3 receptor- and serotonin-mediated diseases.
Type:
Grant
Filed:
June 16, 2006
Date of Patent:
July 13, 2010
Assignee:
Janssen Pharmaceutica NV
Inventors:
Richard Apodaca, Ann J. Barbier, Nicholas I. Carruthers, Leslie A. Gomez, John M. Keith, Timothy W. Lovenberg, Ronald L. Wolin
Abstract: The present invention is directed to novel processes for the preparation of substituted piperazinyl and diazepanyl benzamides of formula (I), as defined in the specification, useful for the treatment of disorders and conditions mediated by the histamine receptor.
Type:
Grant
Filed:
October 26, 2006
Date of Patent:
June 1, 2010
Assignee:
Janssen Pharmaceutica NV
Inventors:
Neelakandha S. Mani, David C. Palmer, Chennagiri R. Pandit, Mayra B. Reyes, Tong Xiao, Sergio Cesco-Cancian
Abstract: An electrotransport device (10) for delivering therapeutic agents includes an adjustable voltage boos multiple controller (100, 200) for boosting the voltage from a power source (102, 202) to a working voltage Vw having a value just sufficient to provide the desired therapeutic current level II through the electrodes (108, 112), at least of which contains the therapeutic agent to be delivered.
Type:
Grant
Filed:
November 30, 2004
Date of Patent:
May 4, 2010
Assignee:
Alza Corporation
Inventors:
Thomas A. Riddle, Larry A. McNichols, John D. Badzinski
Abstract: Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
Type:
Grant
Filed:
December 29, 2005
Date of Patent:
October 6, 2009
Assignee:
Janssen Pharmaceutica N.V.
Inventors:
Richard Apodaca, J. Guy Breitenbucher, Kanaka Pattabiraman, Mark Seierstad, Wei Xiao
Abstract: Certain N-heteroarylpiperazinyl urea compounds of Formula (I), as defined in the specification, are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
Type:
Grant
Filed:
June 28, 2006
Date of Patent:
June 2, 2009
Assignee:
Janssen Pharmaceutica N.V.
Inventors:
Richard Apodaca, J. Guy Breitenbucher, Kanaka Pattabiraman, Mark Seierstad, Wei Xiao
Abstract: A liposome composition and method for delivery of a nucleic acid in vivo or ex vivo is described. The liposomes in the composition are comprised of (i) a cationic lipid and (ii) a lipid joined to a hydrophilic polymer by a releasable linkage. The liposomes are associated with a nucleic acid for delivery to a cell.
Abstract: A method and device are described for applying a microprotrusion member (44) including a plurality of microprotrusions (90) to the stratum corneum with impact. The method and device are used to improve transport of an agent across the skin for agent delivery or sampling. The applicator (10, 60, 80) causes the microprotrusion member (44) to impact the stratum corneum with a certain amount of impact determined to effectively pierce the skin with the microprotrusions (90). The preferred applicator (10, 60, 80) impacts the stratum corneum with the microprotrusion member (44) with an impact of at least 0.05 joules per cm2 of the microprotrusion member (44) in 10 msec or less.
Type:
Grant
Filed:
October 12, 2001
Date of Patent:
November 7, 2006
Assignee:
Alza Corporation
Inventors:
Joseph C. Trautman, Richard L. Keenan, Ahmad P. Samiee, WeiQi Lin, Michel J. N. Cormier, James A. Matriano, Peter E. Daddona
Abstract: An applicator for applying a microprojection member to the stratum corneum of a patient having a housing, a piston moveable within the housing and a cap adapted to activate the applicator. The applicator is self-setting and auto-triggering, which allows the applicator to be used by patient's having neither the strength, nor the manual dexterity to pre-set and activate other types of applicator devices.
Abstract: A method of preparing lipid particles having an asymmetric lipid coating is described. The lipid composition of the outer lipid coating of the particles varies from the inner to outer surfaces. The asymmetric lipid particles are formed by preparing a lipid composition containing a charged lipid and a therapeutic agent, where the particles each have an outer lipid coating with an external lipid leaflet and an internal lipid structure. The particles are then incubated under conditions effective to remove the charged lipid from the external lipid leaflet, thus rendering the lipid coating asymmetric. The particles have the ability to their regain surface charge via translocation of the lipids.
Abstract: The present invention is directed to novel combinations of anti-epileptic compounds that demonstrate pain alleviating properties, with compounds selected from the group consisting of analgesics, N-methyl-D aspartate (NMDA) receptor antagonists and non-steroidal anti-inflammatory drugs (NSAIDS) and pharmaceutical compositions comprising same.
Type:
Grant
Filed:
January 18, 2000
Date of Patent:
July 15, 2003
Assignee:
Warner-Lambert Company
Inventors:
Leslie Magnus-Miller, Douglas A. Saltel
Abstract: Novel combinations of inhibitors of protein farnesyltransferase enzymes and HMG CoA reductases enzymes are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in preventing or treating cancer, restenosis, psoriasis, endometriosis, atherosclerosis, or viral infections.
Abstract: The present invention provides compounds that block calcium channels having the Formula I shown below.
The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.
Inventors:
Richard John Booth, Louis Brogley, Wayne Livingston Cody, David Thomas Connor, Harriet Wall Hamilton, John Xiaoqiang He, Lain-Yen Hu, Leonard Joseph Lescosky, Thomas Charles Malone, Laszlo Nadasdi, Michael Francis Rafferty, Bruce David Roth, Diego F. Silva, Yuntao Song, Balazs G. Szoke, Laszlo Urge
Abstract: Benzimidazoles of Formula I below are inhibitors of protein tyrosine kinases, and are useful in treating cellular proliferation.
The compounds are especially useful in treating cancer, atherosclerosis, restenosis, and psoriasis.
Type:
Grant
Filed:
December 10, 1999
Date of Patent:
April 17, 2001
Assignee:
Warner-Lambert Company
Inventors:
Diane Harris Boschelli, William Alexander Denny, Annette Marian Doherty, James Marino Hamby, Sonya Shah Khatana, James Bernard Kramer, Brian Desmond Palmer, Howard Daniel Hollis Showalter
Abstract: The present invention relates to a composition for the delivery of a pharmaceutical agent to a patient that comprises polyethylene glycol, an aqueous solution containing polyvinylpyrrolidone, and a pharmaceutical agent. The invention also relates to methods of making a composition for the delivery of a pharmaceutical agent.
Type:
Grant
Filed:
October 21, 1998
Date of Patent:
March 27, 2001
Assignee:
Warner-Lambert Company
Inventors:
Howard Yoshihisa Ando, Steven Edward Rose
Abstract: Known cyclic amino acids, such as gabapentin and pregabalin, are used for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants and other addictive drugs/substances. Physiological conditions include stimulant-induced toxicities.
Type:
Grant
Filed:
February 2, 2000
Date of Patent:
February 27, 2001
Assignee:
Warner-Lambert Company
Inventors:
Hyacinth Chi Akunne, Ann Elizabeth Corbin, David James Dooley, Alysia Latrese Green, Thomas Gary Heffner
Abstract: This invention relates to compounds that are antagonists of dopamine D4 receptors, to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors, and to pharmaceutically acceptable compositions that contain a dopamine D4 receptor antagonist.
Type:
Grant
Filed:
November 4, 1998
Date of Patent:
January 23, 2001
Assignee:
Warner-Lambert Company
Inventors:
Thomas R. Belliotti, Lawrence D. Wise, David J. Wustrow
Abstract: A pharmaceutical composition has an acid salt of a sympathomimetic amine; and a denaturant of (i) at least one gum or viscosity modifier, and (ii) at least one surfactant, wherein the gum or viscosity modifier and the surfactant are present in amounts sufficient to have a denaturing effect on the sympathomimetic amine without significantly compromising the release of the sympathomimetic amine from the composition.
Type:
Grant
Filed:
September 25, 1997
Date of Patent:
October 24, 2000
Assignee:
Warner-Lambert Company
Inventors:
W. Michael Nichols, William Bess, Stanley Lech
Abstract: The instant invention is novel uses of known N-(2,6-disubstituted phenyl)-N'-3- and 4-pyridinyl ureas and pharmaceutically acceptable acid addition salts thereof. Such compounds as N-(2-chloro-6-methylphenyl)-N'-4-pyridinyl urea monohydrochloride or N-(2,3-dichlorophenyl)-N'-4-pyridinyl urea are used for treating neurodegenerative disorders, perinatal asphyxia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis. The instant invention is similar novel uses of known anticonvulsant compounds as ralitoline, phenytoin, lamotrigine, tetrodotoxin, lidocaine, and carbamazepine.
Type:
Grant
Filed:
February 25, 1993
Date of Patent:
October 17, 2000
Assignee:
Warner-Lambert Company
Inventors:
Charles Price Taylor, Jr., Mark Lawrence Weber